MedTrace Logo

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

NCT02013492 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-12-06

No results posted yet for this study

Summary

This pilot trial studies propranolol hydrochloride in treating patients with locally recurrent or metastatic solid tumors that cannot be removed by surgery. Propranolol hydrochloride may slow the growth of tumor cells by blocking the use of hormones by the tumor cells.

Conditions

  • Male Breast Cancer
  • Recurrent Melanoma
  • Stage IV Breast Cancer
  • Stage IV Melanoma
  • Stage IV Ovarian Epithelial Cancer
  • Stage IV Ovarian Germ Cell Tumor
  • Unspecified Adult Solid Tumor, Protocol Specific
  • Hepatocellular Carcinoma

Interventions

DRUG

propranolol hydrochloride

Given PO

OTHER

Correlative Studies

Correlative studies will be conducted using the following materials: * Plasma derived from peripheral blood. * Peripheral blood mononuclear cells (PBMC) derived from patient blood * Tumor tissue obtained at the time of core needle biopsy at the 2 month time point. * Paraffin-embedded tumor tissue obtained pre-therapy to make the diagnosis of metastatic disease.

Sponsors & Collaborators

  • William Carson

    lead OTHER

Principal Investigators

  • William Carson, MD · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-21
Primary Completion
2015-06-12
Completion
2015-06-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02013492 on ClinicalTrials.gov